Kensey Nash Reports Third Quarter Record Revenue and Sales
...eriod. This growth is
reflective of the expansion and diversification in our customer base, new
product launches and the successful integration of the macropore
asset acquisition. There were $1.7 million of new product sales resulting
from this acquisition, in addition to substantial increases in sa...
Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
...y $400,000 of new product
sales resulting from the macropore
Biosurgery asset acquisition, and 115%
excluding t... of new product sales
resulting from the Company's macropore
Biosurgery asset acquisition, and
83% excluding th... product revenue related to the
acquisition of the macropore
Biosurgery assets. The success of the
Kensey Nash Reports First Quarter Fiscal Year 2008 Results
...arter. Orthopaedic sales increased 40%
to $6.1 million from $4.4 million in the same period of the prior fiscal
year due to new product sales from the macropore
asset acquisition that was
completed in late fiscal 2007 coupled with strong sales of spine products
from our existing customers. Sales of vascular cl...
product line offers the benefits of resorbable technology as well as ease of customization and use. The macropore
implants are available in the following polymer configuration: 70:30 Poly(L...
Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
... most significant customer in
this market. The increase in spine product sales included $2.0 million of
new product sales resulting from the Company's macropore
acquisition, completed in May 2007. Sales to Orthovita increased $1.9
million due to strong end user sales of existing products and i...